Japanese drugmaker company Shionogi & Co. will invest $2.1 billion to raise its stake in ViiV Healthcare to 21.7%, ...

The New York powerhouse has agreed to surrender its 11.7% interest in the HIV-focused company for $1.875 billion. Under terms ...

By Yadarisa Shabong Jan 20 (Reuters) - Britain's GSK and Japan's Shionogi said on Tuesday that Pfizer will exit their HIV ...

Pfizer Inc. (NYSE:PFE) is included among Dividend Contenders List: Top 20 Stocks. Reuters reported on January 20 that Britain ...

As a result of the acquisition, Pfizer will no longer hold shares of ViiV Healthcare Limited and Shionogi will see its holdings increase to 21.7%. 1 The majority shareholder of ViiV Healthcare Limited ...

Pfizer will relinquish its stake in ViiV Healthcare in a deal valued at just over $2.1 billion that ramps up Shionogi's ...

Shionogi & Co. Ltd. (4507.TO) Osaka Nine Months Ended December 31 GROUP 2025 2024 Revenue Y360.68 bln Y333.60 bln Operating Profit Y148.74 bln Y129.22 bln Pretax Profit Y191.27 bln Y155.88 bln Net ...

OSAKA, Japan--(BUSINESS WIRE)--Shionogi & Co., Ltd. (Head Office: Osaka, Japan; Chief Executive Officer: Isao Teshirogi, Ph.D.; hereafter “Shionogi”) announced the first peer-reviewed publication of ...

OSAKA, Japan--(BUSINESS WIRE)--Shionogi & Co., Ltd. (Head Office: Osaka, Japan; President & CEO: Isao Teshirogi, Ph.D.; hereafter “Shionogi”) announces new data at IDWeek 2024 from PROVE ...

Pfizer exits ViiV Healthcare with a $1.89bn payout, while GSK retains its majority stake amid the shareholder shake-up.

Shionogi Inc., the U.S. subsidiary of Shionogi & Co. Ltd., announced June 2 that current President and CEO Akira Kato will leave the Florham Park division to lead the parent company in Japan. With his ...

As the fight against COVID-19 rolls on, regulators in Japan have bestowed a green light on the country's first homegrown antiviral. The win goes to local drugmaker Shionogi, which has clinched an ...